Medication info

Telostin Tablet 40/10 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Telmisartan›40mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Bright blue oval film-coated tablet
Packaging
30 tablets/box [(10 tablets/PTP*3)]
Approval status
Approval withdrawn

MFDS item code 202001836 · Approved 2020.03.17

This product's status changed to Approval withdrawn on 2024.12.04. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension; improvement of hyperlipidemia; prevention of cardiovascular disease and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of hyperlipidemia; prevention of cardiovascular disease and inhibition of atherosclerosis progression

  • Essential hypertension
  • coronary artery disease
  • peripheral artery disease
  • stroke
  • transient ischemic attack
  • clinical evidence of end-organ damage
  • high-risk diabetes
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
View approved original text

This drug is used for patients who need to take both Telmisartan and Rosuvastatin. Telmisartan primarily helps reduce the risk of myocardial infarction, stroke, and death from cardiovascular diseases in patients over 55 years old with essential hypertension and a high risk of cardiovascular disease. Rosuvastatin lowers cholesterol levels and delays the progression of atherosclerosis in patients with various dyslipidemias, including hypercholesterolemia, when diet and exercise alone are insufficient. Additionally, it is effective in reducing the risk of stroke and myocardial infarction in middle-aged individuals with cardiovascular risk factors and lowers the risk of recurrence after vascular interventions. The combination of both drugs treats hypertension and hyperlipidemia simultaneously and improves cardiovascular health.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan and rosuvastatin components. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg of telmisartan orally once daily; 20 mg once daily may be effective in some patients. If necessary, the dose may be increased to 80 mg once daily. This medicine produces an additional blood pressure-lowering effect when administered with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose of this medicine is 80 mg orally once daily. The risk-reducing effect on cardiovascular morbidity and mortality at doses below 80 mg is unknown. When starting treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be required. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams per day. 2. Elderly patients: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Ethnicity: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients. Patients taking telmisartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amount of each active ingredient) for convenience.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are allergic to this drug, pregnant, breastfeeding, or do not use appropriate contraception should not use it. Patients with severe liver or biliary problems, patients with significantly elevated serum transaminase levels, and patients with muscle diseases should not take this drug. Elderly patients, patients with hyperkalemia, liver dysfunction, cardiovascular disease, gastrointestinal disorders, and reduced renal function should use this drug cautiously and require regular monitoring. If symptoms such as myalgia, muscle weakness, or cramps occur, consult a doctor immediately, and if necessary, blood tests should be conducted to check for muscle damage. This drug may affect liver function, so regular liver function tests are required before and during its use. As blood pressure may decrease too much, if symptoms of hypotension occur, inform medical personnel immediately. There may be interactions with other specific medications, so inform your doctor or pharmacist if you are taking any other medications. Women who are pregnant or planning to become pregnant must consult healthcare professionals before taking this drug and should use appropriate contraception. Breastfeeding women should avoid using this drug or discontinue breastfeeding if they take this drug. Safety and effectiveness have not been established in children, so its use is not recommended. In cases of overdose, symptoms such as hypotension, dizziness, and acute renal failure may occur, so seek medical attention immediately. While taking this drug, drowsiness or dizziness may occur while driving or operating machinery, so caution is advised. This drug should be stored out of reach of children and should not be transferred to another container.

Side effects

Headache, postural dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, elevated ALT, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified gastrointestinal disorders, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory tract infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reaction, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, syncope, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, liver function abnormalities, liver disorders, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute renal failure, chest pain, weakness, influenza-like illness, elevated serum creatinine, increased serum uric acid, elevated liver enzymes, increased serum CK, decreased hemoglobin, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, tinnitus, petechiae, hypoglycemia, vascular edema, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia, drug reaction syndrome with systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, shock, loss of consciousness, liver dysfunction, jaundice, anaphylaxis-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, inadequate effect, facial spasms, sensory abnormalities, paralysis, cough, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, rash, alopecia, conjunctivitis, tinnitus, petechiae, hypoglycemia, vascular edema, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness

Not everyone experiences these, and they can vary from person to person.

Storage

This drug may be sensitive to air or moisture, so it must be stored in a tightly sealed container. Additionally, it is recommended to store the drug at room temperature between 1 to 30 degrees Celsius, and not in excessively hot or cold environments.

Appearance and packaging

Appearance

Bright blue oval film-coated tablet

Package unit

30 tablets/box [(10 tablets/PTP*3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.